Statement of Deviation for Quarter ended 31 March, 2026.
JHS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
JHS Svendgaard Laboratories has filed a statement confirming no deviation in the utilization of Rs. 29.99 crore raised through a Preferential Issue on June 4, 2024. The funds were allocated across three objectives: setting up a new manufacturing project in Jammu & Kashmir under IDS 2021-2030 (Rs. 5.36 crore utilized out of modified allocation of Rs. 6 crore), general corporate purposes (Rs. 7.50 crore fully utilized), and strategic fund infusion into subsidiary JHS Svendgaard Retail Ventures Ltd for expansion (Rs. 1.13 crore utilized out of Rs. 16.50 crore modified allocation). While the original J&K project allocation was Rs. 22.50 crore, it was later modified to Rs. 6 crore, and a new Rs. 16.50 crore allocation was added for the group entity infusion, which was approved by shareholders on July 4, 2024.
No deviation from approved fund utilization means no regulatory concerns, but the significant reallocation from J&K manufacturing to group entity infusion warrants attention as Rs. 15.38 crore of the modified allocation for retail expansion remains undeployed.